Inve India ▾

Bajaj Healthcare share price & results

Bajaj Healthcare Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Vertically integrated Indian pharma manufacturer of APIs, intermediates and finished dosage formulations, and a global-scale producer of Chlorhexidine base and Ascorbic Acid

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue176 ₹ crore+18.9% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin18.0 %0.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit14.0 ₹ crore+27.3% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity10.52 %−2.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin2.87 %+0.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)14.29 %−2.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

9 targets tracked, none judged yet · 9 open · verdicts reflect calls analysed to Q1 FY27.

Bajaj Healthcare Limited management guidance track record on Inve: 9 targets tracked across analysed earnings calls (0 achieved, 0 missed, 9 open).

TargetOriginal wordingSaidLatest callVerdict
Consolidated Revenue Growth10% to 15% for the year 2027
Call transcript, Q1 FY27 · 21 Jul 2026		Q1 FY27Q1 FY27:Guidance of 10-15% growth for FY27 provided.
Call transcript, Q1 FY27 · 21 Jul 2026		New

Source: Inve Guidance Tracker for Bajaj Healthcare Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

9 of Bajaj Healthcare Limited's 9 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 8 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹310.7 +1.06% · +₹3.25

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −32.0% 1Y

₹300₹350₹400₹450Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q1 FY27 — 21 Jul 2026

1Y: ₹456.65 on 24 Oct 2025 → ₹310.7. High ₹481 (30 Oct 2025), low ₹274.95 (18 May 2026).

Previous close
₹307.45
Market cap
₹1.0k Cr
52-week range
₹274.95 – ₹481
One year
−31.68%
Price to earnings (TTM to Sept 2026)
17.67×
Return on equity (TTM to Sept 2026)
10.52%

Overview

Symbol
NSE:BAJAJHCARE
Exchange
NSE
Currency
INR

What Bajaj Healthcare Limited does

Based on the company's own presentations, annual report and earnings calls.

Bajaj Healthcare Limited manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, Finished Dosage Forms (tablets, capsules, powders) and nutraceuticals across facilities in Maharashtra and Gujarat. It is one of the world's major manufacturers of Chlorhexidine base and India's major manufacturer of Ascorbic Acid, and is the only private player undertaking Alkaloid (Opium Gum and Poppy Straw) extraction work for the Government of India. The company also runs a CDMO business making APIs under contract for overseas customers, a dedicated oncology division (Bajaj Oncocare), and is building out peptide synthesis (including GLP-1/Semaglutide) capability.

Segments

  • Active Pharmaceutical Ingredients (APIs)
  • Intermediates
  • Finished Dosage Forms (FDFs)
  • CDMO
  • Alkaloid Processing
  • Bajaj Oncocare
Manufacturing facilities
20 (18 API/Intermediate plants across Tarapur MH, Vadodara & Panoli GJ; 2 FDF plants at Manjusar GJ and Nashik MH)
Dedicated workforce
1,500+
API & Intermediate capacity
730 MT/month APIs + 94 MT/month Intermediates
Finished Dosage Forms capacity
100 Mn pieces/month
Alkaloid processing capacity
250 MTPA Opium Gum, 2,500 MTPA Poppy Straw (Vadodara plant)
Countries with product presence
60+
Founded 1993Headquarters Thane, Maharashtra, IndiaEmployees 1,500 (FY26 (Dec 2025)) Company website

How the price took the results

close before → close after

Q1 FY27
−4.4%
21 Jul

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Bajaj Healthcare Limited

Free account: one company. Everything above stays public.

Write why you follow Bajaj Healthcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Bajaj Healthcare Limited

Guides on how to read this kind of business and the numbers that matter.